Are Regulators Too Hasty in Approving Cancer Drugs?

The British Medical Journal ignited debate earlier last month when it announced that about half of cancer drugs approved by the European Medicines Agency don’t improve survival or quality of life.  The claim begs several complex question: How can regulators evaluate drugs both quickly and effectively?  And whose values should determine access to drugs for deadly and debilitating diseases?

Read more at Institute for Patient Access.